Knowledge Ecology International Europe

Knowledge Ecology International Europe (KEI Europe) is a non-profit organization focusing on the management of knowledge, including innovation and access to knowledge goods.

KEI Europe is a not-for-profit Swiss association with offices in Geneva, Switzerland.

KEI Europe monitors Brussels and Geneva-based trade, health and IPR negotiations, KEI Europe has extensive contacts within governments, academics, consumers organizations and other stakeholders.

As part of its work, KEI Europe endeavors to ensure policy coherence across between positions adopted by the European Union in Brussels with their engagement with global institutions, such as the WHO, WIPO and WTO

http://keieurope.org/actions.html

On 29 April 2022, Knowledge Ecology International Europe (KEI Europe) made the following submission on the European Union’s revised framework for compulsory licensing of patents: https://keieurope.org/2022/04/29/kei-europe-submission-on-eu-revised-framework-for-compulsory-licensing-of-patents/
On 30 March 2022, 42 global and European civil society organizations (including KEI Europe) wrote an open letter calling on the European Union to “refrain from rushing WTO members to rapidly adopt a purported proposal on intellectual property rights and COVID-19.”
On 24 February 2021, KEI Europe submitted comments on the European Health Emergency Preparedness and Response Authority (HERA) roadmap
On 14 August 2020, KEI Europe submitted comments on the Intellectual Property Action Plan
On 7 July 2020, KEI Europe submitted comments on the pharmaceutical strategy roadmap.
On 3 March 2020, KEI Europe submitted comments on the cancer roadmap.


In recent years, KEI Europe has advanced a positive agenda in the Transatlantic Trade and Investment (TTIP) negotiations, submitted a detailed proposal to the Government of the United Kingdom requesting the government to issue a compulsory licence on the costly breast cancer treatment, T-DM1, and engaged in media advocacy with the Franco-German television network, ARTE, on the subject of donor capture of the World Health Organization (WHO).


Horizon 2020


2 February 2017. KEI Europe, along with a coalition of groups, called upon the European Commission to reframe Horizon 2020 to explore alternative models of innovation that delinked the cost of R&D from the price of medicines.

January 2017. The joint submission to the Horizon 2020 consultation established six key recommendations that the European Commission should consider during their review process, including increased public investment in biomedical R&D funding, mandates on open data, and increased transparency.

Transatlantic Trade and Investment Partnership Agreement

24 February 2016. KEI Europe delivered an intervention before EU and US TTIP negotiators as well as stakeholders during the 12th round of negotiations in Brussels.

15 July 2015. KEI Europe presented an intervention on issues related to intellectual property and public health at the TTIP stakeholder event during the negotiations in Brussels.

13 July 2014. KEI Europe Submission: European Commission's Public consultation on modalities for investment protection and ISDS in TTIP.

http://keieurope.org

1

0.5

No lobbyists with EP accreditations

None declared

Data not provided by Register Secretariat due to GDPR

Data not provided by Register Secretariat due to GDPR

Non-governmental organisations, platforms and networks and similar